Blood
Articles in this Issue
Adults with therapy-related acute lymphoblastic leukemia (t-ALL): A systematic review and meta-analysis
Abstract Background: Therapy-related acute lymphoblastic leukemia (t-ALL) is a rare and aggressive subtype of ALL that arises secondary to c...
Hereditary alpha-tryptasemia (HαT) extends the symptom spectrum to cardiovascular, pain and neuropsychiatric symptoms in patients with mast cell-related conditions
Abstract Background: Elevated baseline serum tryptase levels (BST ≥11.5 µg/L) are the hallmark of Hereditary alpha-Tryptasemia (HαT), which...
The development of an off-the-shelf CAR T-cell therapy co-targeting CD19 and CD38 for broad application in autoimmune disease
Abstract CD19-targeting chimeric antigen receptor (CAR) T-cell therapies have demonstrated profound clinical efficacy in the treatment of a...
Human hepatocyte engraftment in F8KO TK-NOG mice: Creating a novel Hemophilia A mouse model with functional human coagulation cascade
Abstract Introduction: Humanized mouse models have been developed to elucidate human-specific responses in various resea...
Prospective study of fluoroquinolone resistance colonization in patients undergoing autologous hematopoietic stem cell transplantation in the treatment of multiple myeloma.
Abstract Fluoroquinolone prophylaxis during the early period of neutropenia is a standard of care after autologous peripheral blood stem cel...
Prognostic value of baseline FDG PET/CT total metabolic tumor volume and MYC/BCL2 double expression status in patients with diffuse large B-cell lymphoma
Abstract Background: Double-expressor lymphoma (DEL) is a distinct entity of diffuse large B-cell lymphoma (DLBCL), characterized by immunohi...
Ultra-low-dose IL-10-expressing CAR-T cells achieve high efficacy in R/R DLBCL: An update analysis
Abstract Context: Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment landscape of relapsed/refractory (R/R) dif...
Serum MMP-7 as an early and specific biomarker for hepatic graft-versus-host disease
Abstract [Introduction] The liver is a major target organ of acute graft-versus-host disease (aGVHD), along with the skin and gastrointestin...
Zanubrutinib plus obinutuzumab induces promising efficacy and a manageable safety profile in previously untreated high-tumor-burden follicular lymphoma
Abstract Background: Although advanced stage follicular lymphoma (FL) is incurable, a majority of newly diagnosed patients achieve long-term...
Single-cell landscape of clonal plasma cells in t(11;14) primary light-chain amyloidosis reveals molecular insights into venetoclax response
Abstract Introduction Venetoclax (Ven), a selective BCL2 inhibitor, has demonstrated promising efficacy in the treatment of primary light-cha...
Predictors of renal recovery in newly diagnosed multiple myeloma with light chain cast nephropathy
Abstract Background: Light chain cast nephropathy (LCCN), characterized by monoclonal free light chain (FLC)–mediated tu...
Transcriptomic analysis uncovers hidden intronic and synonymous pathogenic variants in red cell membrane disorders
Abstract Recessive hereditary spherocytosis (HS) is frequently caused by biallelic pathogenic variants in SPTA1, while monoallelic variants...
TeclistAMY (EMN40): A Phase 2 trial of teclistamab in patients with previously treated light-chain (AL) amyloidosis
Abstract Background: Systemic AL amyloidosis is a rare disorder characterized by the deposition of misfolded monoclonal immunoglobulin light...
Incidence, outcomes and economic burden of cytokine release syndrome and immune effector cell associated neurotoxicity syndrome in patients undergoing CAR-T cell therapy for multiple myeloma
Abstract INTRODUCTION: Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionised the landscape for patients with relapsed/refractor...
Can a patient questionnaire (VRAT) reduce the need for ocular examinations with less frequent belantamab mafodotin combined with bortezomib and dexamethasone? the ukmra prommise d trial
Abstract Introduction: Belantamab Mafodotin (Belamaf) is a BCMA targeted antibody drug conjugate with a multi-modal mechanism of action inclu...
Glofitamab for patients with Non–Large B-cell lymphoma refractory or relapsing after anti-CD19 CAR T-cell therapy: Final bicar study (LYSA) results.
Abstract Introduction. CAR T-cell therapy is indicated for patients with diffuse large B-cell lymphoma as well as for mantle cell lymphomas,...
Major adverse cardiovascular events after teclistamab in relapsed refractory multiple myeloma: A multicenter study from the u.s. multiple myeloma immunotherapy consortium.
Abstract Introduction: Teclistamab is the first FDA approved BCMA-directed bispecific antibody for the treatment of relapsed and refractory m...
Operational efficiencies and cost savings of using one bispecific antibody FDA-approved for both R/R 3L+ DLBCL and FL
Abstract Background: Bispecific antibodies (bsAbs) have been approved for the treatment of relapsed/refractory (R/R) non-Hodgkin's lymphoma...
Trends and disparities in infection-related mortality among non-Hodgkin lymphoma patients in the United States, 1999–2023
Abstract Background: Infection-related mortality remains a significant cause of death in patients with non-Hodgkin lymphoma (NHL), due to bo...
Acquisition of CLL-like epigenetic and transcriptomic states in low-count MBL
Abstract Despite substantial advances in targeted therapies, chronic lymphocytic leukemia (CLL) remains incurable, underscoring the need for...
Challenges in hemoglobinopathy control programs: Insights from Türkiye
Abstract Introduction Hemoglobinopathies are among the most common inherited diseases worldwide. Countries with a high p...
Pre-treatment eosinophil levels correlate with superior clinical outcomes in high tumor burden DLBCL patients receiving CD19 CAR-T cell therapy
Abstract Background Tumor burden is a known negative prognostic factor in diffuse large B-cell lymphoma (DLBCL) and may...
An in vitro hepcidin-FPN AXIS MODEL for exploring the role of macronutrients in cellular iron transport
Abstract Systemic and cellular iron metabolism is tightly regulated, and both its deficiency andexcess lead to major disorders in humans. Th...
Novel CTLA-4 costimulatory domain mitigates cytokine-related toxicity, improving the anti-cancer therapeutic index of CS1-CAR T cells for multiple myeloma
Abstract Multiple myeloma (MM) is a prevalent hematological malignancy in the United States, with approximately 34,000 new cases reported an...
The addition of a tyrosine kinase inhibitor to intensive chemotherapy significantly improves outcome in de novo BCR::ABL1+ acute myeloid leukemia treated with intensive chemotherapy
Abstract Introduction: De novo BCR::ABL1+ acute myeloid leukemia (AML) is a distinct and rare entity (0.1%-3% of AML), classified as adverse...